Literature DB >> 29383396

Differential effects of α4β2 nicotinic receptor antagonists and partial-agonists on contextual fear extinction in male C57BL/6 mice.

Munir Gunes Kutlu1, Jessica M Tumolo2, Courtney Cann3, Thomas J Gould3.   

Abstract

RATIONALE: Numerous studies have attributed the psychopathology of post-traumatic stress disorder (PTSD) to maladaptive behavioral responses such as an inability to extinguish fear. While exposure therapies are mostly effective in treating these disorders by enhancing extinction learning, relapse of PTSD symptoms is common. Although several studies indicated a role for cholinergic transmission and nicotinic acetylcholine receptors (nAChRs) in anxiety and stress disorder symptomatology, very little is known about the specific contribution of nAChRs to fear extinction
OBJECTIVES: In the present study, we examined the effects of inhibition and desensitization of α4β2 nAChRs via a full antagonist (Dihydro-beta-erythroidine (DhβE)) and two α4β2 nAChR partial-agonists (varenicline and sazetidine-A) on contextual fear extinction, locomotor activity, and spontaneous recovery of contextual fear in mice.
METHODS: We trained and tested the subjects in a contextual fear extinction as well as an open field paradigm and spontaneous recovery following injections of DhβE, varenicline, and sazetidine-A.
RESULTS: Our results demonstrated that lower doses of DhβE (1 mg/kg) and sazetidine-A (0.01 mg/kg) enhanced contextual fear extinction whereas higher doses of varenicline (0.1 mg/kg) and sazetidine-A (0.1 mg/kg) resulted in impaired contextual fear extinction. However, the higher dose of sazetidine-A (0.1 mg/kg) decreased locomotor activity, which may contribute to increased freezing response observed during fear extinction. Finally, we found that the low dose of DhβE, but not sazetidine-A, also decreased spontaneous recovery of contextual fear following fear extinction.
CONCLUSIONS: Overall, these results suggest that inhibition and desensitization of α4β2 nAChRs enhance extinction of contextual fear memories. This suggests that modulation of α4β2 nAChRs may be employed as an alternative pharmacological strategy to aid exposure therapies associated with PTSD by augmenting contextual fear extinction processes.

Entities:  

Keywords:  Fear extinction; Nicotinic receptors; PTSD; Spontaneous recovery

Mesh:

Substances:

Year:  2018        PMID: 29383396      PMCID: PMC5871575          DOI: 10.1007/s00213-018-4837-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

1.  Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior.

Authors:  Jill R Turner; Laura M Castellano; Julie A Blendy
Journal:  J Pharmacol Exp Ther       Date:  2010-04-30       Impact factor: 4.030

2.  Pre-adolescent and adolescent mice are less sensitive to the effects of acute nicotine on extinction and spontaneous recovery.

Authors:  Munir Gunes Kutlu; Dana Zeid; Jessica M Tumolo; Thomas J Gould
Journal:  Brain Res Bull       Date:  2017-06-15       Impact factor: 4.077

3.  Posttraumatic stress disorder and the incidence of nicotine, alcohol, and other drug disorders in persons who have experienced trauma.

Authors:  Naomi Breslau; Glenn C Davis; Lonni R Schultz
Journal:  Arch Gen Psychiatry       Date:  2003-03

4.  High-affinity α4β2 nicotinic receptors mediate the impairing effects of acute nicotine on contextual fear extinction.

Authors:  Munir Gunes Kutlu; Erica Holliday; Thomas J Gould
Journal:  Neurobiol Learn Mem       Date:  2015-12-11       Impact factor: 2.877

5.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

Review 6.  From Pavlov to PTSD: the extinction of conditioned fear in rodents, humans, and anxiety disorders.

Authors:  Michael B VanElzakker; M Kathryn Dahlgren; F Caroline Davis; Stacey Dubois; Lisa M Shin
Journal:  Neurobiol Learn Mem       Date:  2013-12-07       Impact factor: 2.877

7.  Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice.

Authors:  Jonathan D Raybuck; George S Portugal; Caryn Lerman; Thomas J Gould
Journal:  Behav Neurosci       Date:  2008-10       Impact factor: 1.912

8.  Meta-analysis of dropout in treatments for posttraumatic stress disorder.

Authors:  Zac E Imel; Kevin Laska; Matthew Jakupcak; Tracy L Simpson
Journal:  J Consult Clin Psychol       Date:  2013-01-21

9.  Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat.

Authors:  E Wada; K Wada; J Boulter; E Deneris; S Heinemann; J Patrick; L W Swanson
Journal:  J Comp Neurol       Date:  1989-06-08       Impact factor: 3.215

10.  Acute nicotine enhances spontaneous recovery of contextual fear and changes c-fos early gene expression in infralimbic cortex, hippocampus, and amygdala.

Authors:  Munir G Kutlu; Jessica M Tumolo; Erica Holliday; Brendan Garrett; Thomas J Gould
Journal:  Learn Mem       Date:  2016-07-15       Impact factor: 2.460

View more
  2 in total

1.  Nicotine modulates contextual fear extinction through changes in ventral hippocampal GABAergic function.

Authors:  Munir Gunes Kutlu; David A Connor; Jessica M Tumolo; Courtney Cann; Brendan Garrett; Thomas J Gould
Journal:  Neuropharmacology       Date:  2018-08-28       Impact factor: 5.250

2.  Nicotine Activating α4β2 Nicotinic Acetylcholine Receptors to Suppress Neuroinflammation via JAK2-STAT3 Signaling Pathway in Ischemic Rats and Inflammatory Cells.

Authors:  Qi Wang; Jinyu Gou; Shenrui Guo; Feng Wei; Tingting Han; Ruihe Lai; Dalong Zhang; Yao Diao; Yafu Yin
Journal:  Mol Neurobiol       Date:  2022-03-17       Impact factor: 5.590

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.